Signaling pathways in lymphoma: pathogenesis and therapeutic targets.
about
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasPhase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.The Expression of CD9 and PIK3CD is Associated with Prognosis of Follicular Lymphoma.Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.
P2860
Signaling pathways in lymphoma: pathogenesis and therapeutic targets.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Signaling pathways in lymphoma: pathogenesis and therapeutic targets.
@en
type
label
Signaling pathways in lymphoma: pathogenesis and therapeutic targets.
@en
prefLabel
Signaling pathways in lymphoma: pathogenesis and therapeutic targets.
@en
P2093
P2860
P356
P1433
P1476
Signaling pathways in lymphoma: pathogenesis and therapeutic targets.
@en
P2093
Adriana Arita
Bruce Petersen
Janice Gabrilove
Joshua D Brody
Samir Parekh
P2860
P304
P356
10.2217/FON.13.113
P407
P577
2013-10-01T00:00:00Z